Melanoma Clinical Trial
— FADEMELAOfficial title:
Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
Verified date | July 2019 |
Source | University Hospital, Tours |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
First-degree relatives of patients with melanoma have a greater risk of developing melanoma. Patients are advised orally to inform their first-degree relatives that they should protect their skin from UV radiation and ask for a skin examination from a general practitioner or dermatologist. The study will evaluate the effectiveness of a written sheet in addition to the usual oral counselling to increase acceptance of skin examination by the first-degree relatives. If effective, written counselling provided to the patient for relatives should be recommended and generalized.
Status | Completed |
Enrollment | 420 |
Est. completion date | July 10, 2019 |
Est. primary completion date | April 26, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: For Patients: - Personal history of Stage 0 through IIB melanoma - At maximum of 12 weeks after surgical treatment of Stage 0 through IIA melanoma - Have at least one first-degree relative - Speaking and reading French - Affiliated to the French Health Insurance system - Signed non-opposition form at the 1 year consultation For 1st degree relatives: - To be 1st degree related to a patient with melanoma - Speaking and reading French - 1st degree relatives informed by patients and agreeing to fill out the psychological questionnaires and to the use of their personal data by the investigators. |
Country | Name | City | State |
---|---|---|---|
France | CHU - ANGERS , Service de Dermatologie | Angers | |
France | CHRU BREST Hôpital du Morvan, Institut de Cancérologie et d'Hématologie | Brest | |
France | GH La Rochelle Ré Aunis-Service de Dermatologie | La Rochelle | |
France | Ch Le Mans | Le Mans | |
France | CHU NANTES, Service de Dermatologie | Nantes | |
France | CHU-Poitiers _LA MILETRIE POLE MEDIPOOL-DERMATO-ALLERGOLOGIE | Poitiers | |
France | Centre Eugène Marquis -Service d'Oncologie médicale | Rennes | |
France | CHU -RENNES -Service de Dermatologie-CHU Pontchaillou | Rennes | |
France | University Hospital of Tours, Service de Dermatologie | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Tours | Institut d'Enseignement à Distance,University Paris - 8, Institut national de la santé et de la recherche médicale, CIC 1415, TOURS, Institut national de la santé et de la recherche médicale, U930,TOURS |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Consulting general practitioner or dermatologist | The number of relatives who will have consulted a dermatologist or a general practitioner to perform whole body skin examination | 1 year | |
Secondary | Self-skin examination reported by the relatives | The number of relatives who declare to have performed Self-skin examination. | 1 year | |
Secondary | Sun protection behaviors reported by the relatives | Sun protection behaviours reported by the relatives and assessed by a questionnaire | 1 year | |
Secondary | Barriers to skin examination identified from psychological questionnaires in patients and their relatives | Psychological barriers of patients and their relatives to skin examination evaluated with several questionnaires and scales. | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT03979872 -
Risk Information and Skin-cancer Education for Undergraduate Prevention
|
N/A | |
Recruiting |
NCT04986748 -
Using QPOP to Predict Treatment for Sarcomas and Melanomas
|
||
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Recruiting |
NCT05707286 -
Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
|
||
Active, not recruiting |
NCT05470283 -
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
|
Phase 1 | |
Recruiting |
NCT05077137 -
A Feasibility Study Utilizing Immune Recall to Increase Response to Checkpoint Therapy
|
Phase 1 | |
Active, not recruiting |
NCT02721459 -
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
|
Phase 1 | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Recruiting |
NCT05839912 -
Excision of Lymph Node Trial (EXCILYNT) (Mel69)
|
N/A | |
Recruiting |
NCT04971499 -
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05263453 -
HL-085+Vemurafenib to Treat Advanced Melanoma Patients With BRAF V600E/K Mutation
|
Phase 2 | |
Active, not recruiting |
NCT05060432 -
Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06413680 -
A First-In Human (FIH) Trial to Find Out if REGN10597 is Safe and How Well it Works for Adult Participants With Advanced Solid Organ Malignancies
|
Phase 1/Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03348891 -
TNF in Melanoma Patients Treated With Immunotherapy
|
N/A | |
Completed |
NCT03171064 -
Exercise as a Supportive Measure for Patients Undergoing Checkpoint-inhibitor Treatment
|
Phase 2 | |
Not yet recruiting |
NCT05539118 -
Interferon-α1b Combined With Toripalimab and Anlotinib Hydrochloride in Advanced Unresectable Melanoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT05171374 -
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIс melanOma Treated With dabrafeNib and trAmetinib in reaL practicE
|
||
Withdrawn |
NCT02854488 -
Yervoy Pregnancy Surveillance Study
|